Arrowhead Pharmaceuticals to Announce Q1 Earnings Amid Market Weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Should l Buy ARWR?
Source: Benzinga
Arrowhead Pharmaceuticals Inc. shares fell 5.14% today, crossing below the 20-day SMA, as the broader market faced declines with the Nasdaq-100 down 1.61% and the S&P 500 down 1.38%.
The company is set to announce its Q1 earnings on February 5th, with a consensus EPS estimate of -$0.37 and revenue expected at $230.85 million, a significant increase from $2.5 million in Q1 FY2025. However, historical performance shows that Arrowhead has only beaten EPS estimates 13% of the time, which may contribute to investor uncertainty. Additionally, the recent upsizing of its convertible notes offering to $625 million and the approval of Redemplo in China for high triglycerides indicate positive developments, but the mixed revisions in earnings estimates suggest a divergence in market sentiment.
The upcoming earnings report could be pivotal for Arrowhead, as it may influence investor confidence and stock performance moving forward, especially in light of the recent market downturn.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARWR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 75.50 USD with a low forecast of 35.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 64.640
Low
35.00
Averages
75.50
High
100.00
Current: 64.640
Low
35.00
Averages
75.50
High
100.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arrowhead Pharmaceuticals Q1 2026 Earnings Call Highlights
- FDA Approval of New Drug: Arrowhead received FDA approval and launched REDEMPLO in the U.S. for familial chylomicronemia syndrome, marking the company's first regulatory approval and initiating a new phase as a commercial entity, which is expected to drive revenue growth.
- Strong Financial Performance: For Q4 2025, net income was $30.8 million with earnings per share of $0.22, and total revenue reached $264 million, primarily driven by licensing and collaboration agreements with Sarepta and Novartis, showcasing the company's strong execution in the market.
- Successful Capital Raising: The company completed $1.33 billion in capital raising during the reporting period, including a $200 million upfront payment from Novartis and a $200 million milestone payment from Sarepta, providing robust funding support for future R&D and commercialization efforts.
- Optimistic Future Outlook: Management anticipates achieving positive cash flow through multiple independent and partnered product launches, emphasizing the commercial sales progress of REDEMPLO and upcoming key clinical data releases, indicating significant growth potential for the company in the coming years.
See More
Arrowhead Pharmaceuticals Q1 Earnings Exceed Expectations
- Earnings Beat: Arrowhead Pharmaceuticals reported a Q1 GAAP EPS of $0.22, surpassing expectations by $0.37, indicating strong profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $264.03 million, exceeding market expectations of $230.85 million, reflecting sustained demand for its products and further solidifying its market position.
- Stock Performance Volatility: Despite the earnings beat, Arrowhead's shares fell by 2%, indicating market caution regarding future growth, which may impact short-term investor sentiment.
- Expanded Financing Plans: Arrowhead upsized its convertible notes offering to $625 million and priced its stock offering at $64.50 per share, demonstrating a proactive approach to future expansion and R&D investments.
See More
Arrowhead Pharmaceuticals Set to Announce Q1 Earnings on February 5th
- Earnings Announcement: Arrowhead Pharmaceuticals is set to release its Q1 earnings on February 5th after market close, with consensus EPS estimate at -$0.37 and revenue expected at $230.85 million, a significant increase from $2.5 million in Q1 FY2025, indicating potential revenue growth for the company.
- Historical Performance Review: Over the past two years, Arrowhead has only beaten EPS estimates 13% of the time and revenue estimates 38% of the time, reflecting uncertainty in financial performance that may impact investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates experienced two upward revisions and four downward changes, suggesting market divergence regarding the company's future performance.
- Financing and Product Approval: Arrowhead recently upsized its convertible notes offering to $625 million and conducted a stock offering at $64.50 per share, while also gaining approval for Redemplo in China for high triglycerides, demonstrating positive progress in financing and product development.
See More
Privium Fund Management Reduces Arrowhead Holdings
- Share Reduction Details: Privium Fund Management disclosed in a February 2 SEC filing that it reduced its position in Arrowhead Pharmaceuticals by 75,747 shares in Q4, with an estimated trade value of $3.71 million, reflecting a risk management strategy.
- Position Value Surge: Despite the reduction, the value of Arrowhead in Privium's portfolio surged by $10.09 million at quarter-end, indicating a strong stock price increase of 289.5% year-over-year, significantly outperforming the S&P 500's 15% gain.
- Financial Performance: Arrowhead's fiscal 2025 revenue is projected to reach $829 million, a substantial increase from $3.6 million the previous year, primarily driven by licensing and milestone payments, showcasing accelerated commercialization efforts.
- Investor Confidence Signal: After the sale, Arrowhead still represents 4.87% of Privium's 13F U.S. equity AUM, indicating sustained confidence in Arrowhead while locking in some gains to manage market volatility within a high-risk portfolio.
See More
Privium Fund Management Sells Arrowhead Shares
- Sale Overview: Privium Fund Management sold 75,747 shares of Arrowhead Pharmaceuticals in Q4, with an estimated transaction value of $3.71 million, demonstrating the fund's agility in navigating market fluctuations.
- Position Value Increase: Despite the sale, Privium's position in Arrowhead increased by $10.09 million, reflecting the stock's robust price appreciation and indicating strong market confidence in the company's future prospects.
- Position Proportion Analysis: Following the transaction, Arrowhead represents 4.87% of Privium's 13F U.S. equity AUM, highlighting the fund's continued optimism towards the company even after partial divestment.
- Financial Performance Highlights: Arrowhead's fiscal 2025 revenue is projected to surge to $829 million from just $3.6 million last year, showcasing the success of its commercialization efforts and strong market demand.
See More
Longevity Infrastructure Market Undergoes Structural Reset
- Market Size Surge: The global longevity infrastructure is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Growth: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are set to accelerate to $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell encapsulation technology and precision metabolic delivery.
- Technological Innovation Breakthrough: Avant Technologies' Cell-in-a-Box® technology addresses the critical issue of transplanted cells being destroyed by the immune system by creating a protective barrier around them, thus eliminating the need for immunosuppressive drugs and enhancing the safety and scalability of diabetes therapies.
- Massive Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SG Austria to develop a bioartificial pancreas aims to restore natural glucose control and meet the demands of this vast market.
See More
Arrowhead Pharmaceuticals Q1 2026 Earnings Call Highlights
- FDA Approval of New Drug: Arrowhead received FDA approval and launched REDEMPLO in the U.S. for familial chylomicronemia syndrome, marking the company's first regulatory approval and initiating a new phase as a commercial entity, which is expected to drive revenue growth.
- Strong Financial Performance: For Q4 2025, net income was $30.8 million with earnings per share of $0.22, and total revenue reached $264 million, primarily driven by licensing and collaboration agreements with Sarepta and Novartis, showcasing the company's strong execution in the market.
- Successful Capital Raising: The company completed $1.33 billion in capital raising during the reporting period, including a $200 million upfront payment from Novartis and a $200 million milestone payment from Sarepta, providing robust funding support for future R&D and commercialization efforts.
- Optimistic Future Outlook: Management anticipates achieving positive cash flow through multiple independent and partnered product launches, emphasizing the commercial sales progress of REDEMPLO and upcoming key clinical data releases, indicating significant growth potential for the company in the coming years.
See More
Arrowhead Pharmaceuticals Q1 Earnings Exceed Expectations
- Earnings Beat: Arrowhead Pharmaceuticals reported a Q1 GAAP EPS of $0.22, surpassing expectations by $0.37, indicating strong profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $264.03 million, exceeding market expectations of $230.85 million, reflecting sustained demand for its products and further solidifying its market position.
- Stock Performance Volatility: Despite the earnings beat, Arrowhead's shares fell by 2%, indicating market caution regarding future growth, which may impact short-term investor sentiment.
- Expanded Financing Plans: Arrowhead upsized its convertible notes offering to $625 million and priced its stock offering at $64.50 per share, demonstrating a proactive approach to future expansion and R&D investments.
See More
Arrowhead Pharmaceuticals Set to Announce Q1 Earnings on February 5th
- Earnings Announcement: Arrowhead Pharmaceuticals is set to release its Q1 earnings on February 5th after market close, with consensus EPS estimate at -$0.37 and revenue expected at $230.85 million, a significant increase from $2.5 million in Q1 FY2025, indicating potential revenue growth for the company.
- Historical Performance Review: Over the past two years, Arrowhead has only beaten EPS estimates 13% of the time and revenue estimates 38% of the time, reflecting uncertainty in financial performance that may impact investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates experienced two upward revisions and four downward changes, suggesting market divergence regarding the company's future performance.
- Financing and Product Approval: Arrowhead recently upsized its convertible notes offering to $625 million and conducted a stock offering at $64.50 per share, while also gaining approval for Redemplo in China for high triglycerides, demonstrating positive progress in financing and product development.
See More
Privium Fund Management Reduces Arrowhead Holdings
- Share Reduction Details: Privium Fund Management disclosed in a February 2 SEC filing that it reduced its position in Arrowhead Pharmaceuticals by 75,747 shares in Q4, with an estimated trade value of $3.71 million, reflecting a risk management strategy.
- Position Value Surge: Despite the reduction, the value of Arrowhead in Privium's portfolio surged by $10.09 million at quarter-end, indicating a strong stock price increase of 289.5% year-over-year, significantly outperforming the S&P 500's 15% gain.
- Financial Performance: Arrowhead's fiscal 2025 revenue is projected to reach $829 million, a substantial increase from $3.6 million the previous year, primarily driven by licensing and milestone payments, showcasing accelerated commercialization efforts.
- Investor Confidence Signal: After the sale, Arrowhead still represents 4.87% of Privium's 13F U.S. equity AUM, indicating sustained confidence in Arrowhead while locking in some gains to manage market volatility within a high-risk portfolio.
See More
Privium Fund Management Sells Arrowhead Shares
- Sale Overview: Privium Fund Management sold 75,747 shares of Arrowhead Pharmaceuticals in Q4, with an estimated transaction value of $3.71 million, demonstrating the fund's agility in navigating market fluctuations.
- Position Value Increase: Despite the sale, Privium's position in Arrowhead increased by $10.09 million, reflecting the stock's robust price appreciation and indicating strong market confidence in the company's future prospects.
- Position Proportion Analysis: Following the transaction, Arrowhead represents 4.87% of Privium's 13F U.S. equity AUM, highlighting the fund's continued optimism towards the company even after partial divestment.
- Financial Performance Highlights: Arrowhead's fiscal 2025 revenue is projected to surge to $829 million from just $3.6 million last year, showcasing the success of its commercialization efforts and strong market demand.
See More
Longevity Infrastructure Market Undergoes Structural Reset
- Market Size Surge: The global longevity infrastructure is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Growth: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are set to accelerate to $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell encapsulation technology and precision metabolic delivery.
- Technological Innovation Breakthrough: Avant Technologies' Cell-in-a-Box® technology addresses the critical issue of transplanted cells being destroyed by the immune system by creating a protective barrier around them, thus eliminating the need for immunosuppressive drugs and enhancing the safety and scalability of diabetes therapies.
- Massive Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SG Austria to develop a bioartificial pancreas aims to restore natural glucose control and meet the demands of this vast market.
See More
